Pathogenesis of Human Gammaherpesviruses: Recent Advances.

IF 3.1 Q2 MICROBIOLOGY Current Clinical Microbiology Reports Pub Date : 2019-01-01 Epub Date: 2019-08-01 DOI:10.1007/s40588-019-00127-2

Darin J Weed, Blossom Damania

引用次数: 0

Abstract

Purpose of this review: Human gammaherpesviruses have complex lifecycles that drive their pathogenesis. KSHV and EBV are the etiological agents of multiple cancers worldwide. There is no FDA-approved vaccine for either KSHV or EBV. This review will describe recent progress in understanding EBV and KSHV lifecycles during infection.

Recent findings: Determining how latency is established, particularly how non-coding RNAs influence latent and lytic infection, is a rapidly growing area of investigation into how gammaherpesviruses successfully persist in the human population. Many factors have been identified as restrictors of reactivation from latency, especially innate immune antagonism. Finally, new host proteins that play a role in lytic replication have been identified.

Summary: In this review we discuss recent findings over the last 5 years on both host and viral factors that are involved in EBV and KSHV pathogenesis.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

人类γ疱疹病毒的发病机制：最新进展。

本综述的目的：人类γ疱疹病毒具有复杂的生命周期，是其致病机理的驱动因素。KSHV 和 EBV 是全球多种癌症的病原体。目前还没有针对 KSHV 或 EBV 的疫苗获得 FDA 批准。本综述将介绍在了解 EBV 和 KSHV 感染期间生命周期方面的最新进展：确定潜伏期是如何建立的，特别是非编码 RNA 如何影响潜伏感染和溶解感染，是研究γ疱疹病毒如何在人类群体中成功存活的一个快速增长的领域。许多因素，尤其是先天性免疫拮抗因素已被确定为从潜伏期重新激活的限制因素。摘要：在这篇综述中，我们讨论了过去 5 年中有关 EBV 和 KSHV 发病机制中宿主和病毒因素的最新发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Clinical Microbiology Reports MICROBIOLOGY-

CiteScore

7.50

自引率

1.90%

发文量

期刊介绍： Current Clinical Microbiology Reports commissions expert reviews from leading scientists at the forefront of research in microbiology. The journal covers this broad field by dividing it into four key main areas of study: virology, bacteriology, parasitology, and mycology. Within each of the four sections, experts from around the world address important aspects of clinical microbiology such as immunology, diagnostics, therapeutics, antibiotics and antibiotic resistance, and vaccines. Some of the world’s foremost authorities in the field of microbiology serve as section editors and editorial board members. Section editors select topics for which leading researchers are invited to contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, which are highlighted in annotated reference lists. These timely reviews of the literature examine the latest scientific discoveries and controversies as they emerge and are indispensable to both researchers and clinicians. The editorial board, composed of more than 20 internationally diverse members, reviews the annual table of contents, ensures that topics address all aspects of emerging research, and where applicable suggests topics of critical importance to various countries/regions.